This site is intended for Healthcare professionals only.

Bristol-Myers Squibb buying Celgene in Rs 7400 crores deal


Bristol-Myers Squibb buying Celgene in Rs 7400 crores deal
They’ll also receive one tradable contingent value right for each Celgene share, allowing the holder to receive a payment when future regulatory milestones are hit. The combined company will have nine products with more than USD 1 billion in annual sales and significant potential for growth in the core disease areas of oncology, immunology and inflammation and cardiovascular disease.

Shareholders of Bristol-Myers Squibb Co, based in New York City, would own about 69 per cent of the company, with Celgene shareholders owning about 31 per cent.

Bristol-Myers Squibb Company (BMS) is an American pharmaceutical company, manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.

Read Also: Bristol-Myers Squibb collaborates with Harvard for new fibrosis research



Source: With input
0 comment(s) on Bristol-Myers Squibb buying Celgene in Rs 7400 crores deal

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted